<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-IPR-15005779</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2014-12-29</date_registration>
      <primary_sponsor>First Affilited Hospital of Guangxi Medical University</primary_sponsor>
      <public_title>Efficacy of different dosage of antithymocyte globulin in HLA-matched allogeneic hematopoietic stem cell transplantation for thalassemia major treatment: a multi-center, open, randomized, controlled clinical study</public_title>
      <acronym />
      <scientific_title>Efficacy of different dosage of antithymocyte globulin in HLA-matched allogeneic hematopoietic stem cell transplantation for thalassemia major treatment: a multi-center, open, randomized, controlled clinical study</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2015-03-01</date_enrolment>
      <type_enrolment />
      <target_size>control group:50;experimental group :50;</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=10208</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>IV (Phase IV study)</phase>
      <hc_freetext>thalassemia major</hc_freetext>
      <i_freetext>control group:Busulfan+fludarabine+cyclophosphamiade+antithymocyte globulin(10mg/kg);experimental group :Busulfan+fludarabine+cyclophosphamiade+antithymocyte globulin(8mg/kg);</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Zhongming Zhang</firstname>
        <middlename />
        <lastname />
        <address>6 Shuangyong road, Qingxiu district, Nanning, Guangxi Zhuang Autonomous Region</address>
        <city />
        <country1 />
        <zip>530021</zip>
        <telephone>+86 15807801369</telephone>
        <email>zzmmissyou@126.com</email>
        <affiliation>the First Affilited Hospital of Guangxi Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Yongrong Lai</firstname>
        <middlename />
        <lastname />
        <address>6 Shuangyong road, Qingxiu district, Nanning, Guangxi Zhuang Autonomous Region</address>
        <city />
        <country1 />
        <zip>530021</zip>
        <telephone>+86 13517711828</telephone>
        <email>laiyongrong@263.net</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Age: 2 to 18 years old;
2. Gender: Male or female;
3. Thalassemia major;
4. HLA-matched related hematopoietic stem cell transplantation;
5. no sereve infection;
6. In good general condition, ECOG score less than 1;
7. Normal heart function: ejection fraction more than 50%;
8. Normal liver and renal function: Serum bilirubin less than 35umol/L, AST/ALT less than 2 times the upper limit, serum creatinine under 2 times the upper limit;
9. Enrolled subjects or their families signed informed consent.</inclusion_criteria>
      <agemin>1</agemin>
      <agemax>18</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. severe infection uncontrolled before transplantation;
2. severe allergic on Antithymocyte globulin (anaphylactic shock or laryngeal edema);
3. unrelated allogeneic hematopoietic stem cell transplantation;Hyplotype allogeneic hematopoietic stem cell transplantation; second transplantation, reduced-intensisty transplantation;
4. Cardiac dysfunction (ejection fraction less than 50%);
5. Renal insufficiency (serum creatinine more than 130umol/L);
6. Hepatic dysfunction (total bilirubin more than 34umol/L, ALT, AST more than 2 times the upper limit of normal);
7. Previously history of allogeneic hematopoietic stem cell transplantation;
8. Other circumstances which do not meet the inclusion criteria.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>over-survival;disease-free survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>self-financing</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-02-11</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>